Literature DB >> 26775238

Sialoadhesin promotes neuroinflammation-related disease progression in two mouse models of CLN disease.

Janos Groh1, Eliana Ribechini2, David Stadler1, Tim Schilling1, Manfred B Lutz2, Rudolf Martini1.   

Abstract

CLN diseases are mostly fatal lysosomal storage diseases that lead to neurodegeneration in the CNS. We have previously shown that CD8+ T-lymphocytes contribute to axonal perturbation and neuron loss in the CNS of Ppt1(-/-) mice, a model of CLN1 disease. We now investigated the role of the inflammation-related cell adhesion molecule sialoadhesin (Sn) in Ppt1(-/-) and Cln3(-/-) mice, a model of the most frequent form, CLN3 disease. Microglia/macrophages in the CNS of both models showed an upregulation of Sn and markers for proinflammatory M1 polarization and antigen presentation. Sn+ microglia/macrophages associated with SMI32+ axonal spheroids and CD8+ T-lymphocytes. To analyze their pathogenic impact, we crossbred both models with Sn-deficient mice and scored axonal degeneration and neuronal integrity using immunohistochemistry, electron microscopy and optical coherence tomography. Degenerative alterations in the retinotectal pathway of Ppt1(-/-)Sn(-/-) and Cln3(-/-)Sn(-/-) mice were significantly reduced. Ppt1(-/-)Sn(-/-) mice also showed a substantially improved clinical phenotype and extended lifespan, attenuated numbers of M1-polarized microglia/macrophages and reduced expression levels of proinflammatory cytokines. This was accompanied by an increased frequency of CD8+CD122+ T-lymphocytes in the CNS of Ppt1(-/-)Sn(-/-) mice, the regulatory phenotype of which was demonstrated by impaired survival of CD8+CD122- effector T-lymphocytes in co-culture experiments. We show for the first time that increased Sn expression on microglia/macrophages contributes to neural perturbation in two distinct models of CLN disease. Our data also indicate that a rarely described CD8+CD122+ T-cell population can regulate the corresponding diseases. These studies provide insights into CLN pathogenesis and may guide in designing immuno-regulatory treatment strategies.
© 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  T-lymphocytes; immune regulation; microglia; neurodegeneration; neuroinflammation; neuronal ceroid lipofuscinosis

Mesh:

Substances:

Year:  2016        PMID: 26775238     DOI: 10.1002/glia.22962

Source DB:  PubMed          Journal:  Glia        ISSN: 0894-1491            Impact factor:   7.452


  21 in total

1.  Progress toward Fulfilling the Potential of Immunomodulation in Childhood Neurodegeneration?

Authors:  Jonathan D Cooper; Hemanth R Nelvagal
Journal:  Mol Ther       Date:  2017-06-16       Impact factor: 11.454

Review 2.  Recent Insight into the Genetic Basis, Clinical Features, and Diagnostic Methods for Neuronal Ceroid Lipofuscinosis.

Authors:  Konrad Kaminiów; Sylwia Kozak; Justyna Paprocka
Journal:  Int J Mol Sci       Date:  2022-05-20       Impact factor: 6.208

Review 3.  Therapeutic landscape for Batten disease: current treatments and future prospects.

Authors:  Tyler B Johnson; Jacob T Cain; Katherine A White; Denia Ramirez-Montealegre; David A Pearce; Jill M Weimer
Journal:  Nat Rev Neurol       Date:  2019-03       Impact factor: 42.937

4.  Characterization of neurological disease progression in a canine model of CLN5 neuronal ceroid lipofuscinosis.

Authors:  Elizabeth J Meiman; Grace Robinson Kick; Cheryl A Jensen; Joan R Coates; Martin L Katz
Journal:  Dev Neurobiol       Date:  2022-04-28       Impact factor: 3.102

Review 5.  Glial Dysfunction and Its Contribution to the Pathogenesis of the Neuronal Ceroid Lipofuscinoses.

Authors:  Keigo Takahashi; Hemanth R Nelvagal; Jenny Lange; Jonathan D Cooper
Journal:  Front Neurol       Date:  2022-04-04       Impact factor: 4.086

6.  Neurodegeneration and Epilepsy in a Zebrafish Model of CLN3 Disease (Batten Disease).

Authors:  Kim Wager; Anselm A Zdebik; Sonia Fu; Jonathan D Cooper; Robert J Harvey; Claire Russell
Journal:  PLoS One       Date:  2016-06-21       Impact factor: 3.240

7.  Fingolimod and Teriflunomide Attenuate Neurodegeneration in Mouse Models of Neuronal Ceroid Lipofuscinosis.

Authors:  Janos Groh; Kristina Berve; Rudolf Martini
Journal:  Mol Ther       Date:  2017-05-13       Impact factor: 11.454

8.  Teriflunomide attenuates neuroinflammation-related neural damage in mice carrying human PLP1 mutations.

Authors:  Janos Groh; Michaela Hörner; Rudolf Martini
Journal:  J Neuroinflammation       Date:  2018-07-03       Impact factor: 8.322

9.  Lipid-induced lysosomal damage after demyelination corrupts microglia protective function in lysosomal storage disorders.

Authors:  Enrique Gabandé-Rodríguez; Azucena Pérez-Cañamás; Beatriz Soto-Huelin; Daniel N Mitroi; Sara Sánchez-Redondo; Elena Martínez-Sáez; César Venero; Héctor Peinado; María Dolores Ledesma
Journal:  EMBO J       Date:  2018-12-07       Impact factor: 11.598

Review 10.  Microglial Lectins in Health and Neurological Diseases.

Authors:  Jian Jing Siew; Yijuang Chern
Journal:  Front Mol Neurosci       Date:  2018-05-14       Impact factor: 5.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.